This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Sept. 5, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that
Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following upcoming healthcare investor conferences:
STIFEL NICOLAUS 2012 HEALTHCARE CONFERENCE- Presentation Date:
Thursday, September 6, 2012- Presentation Time:
RODMAN & RENSHAW ANNUAL GLOBAL INVESTMENT CONFERENCE- Presentation Date:
Monday, September 10, 2012- Presentation Time: 3:40pm ET
2012 UBS GLOBAL LIFE SCIENCES CONFERENCE- Presentation Date:
Thursday, September 20, 2012- Presentation Time:
Each of these presentations will be live audio webcast and accessible from the Investor Information page of the Company's Website at
http://investors.keryx.com. An archived version of each webcast will be available following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.
Lauren FischerDirector - Investor RelationsKeryx Biopharmaceuticals, Inc.Tel: 212.531.5965E-mail:
SOURCE Keryx Biopharmaceuticals, Inc.